@article{db3bf2417c6a4dbd9606bf2bd62ed236,
title = "Abrocitinib for atopic dermatitis – Authors' reply",
author = "Simpson, {Eric L.} and Thomas Bieber and Thyssen, {Jacob P.} and Hernan Valdez and Ricardo Rojo",
note = "Funding Information: ELS is a consultant for Pfizer, AbbVie, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, Menlo Therapeutics, LEO Pharma, and Regeneron; and a principal investigator for AbbVie, GlaxoSmithKline, LEO Pharma, Novartis, Regeneron, Tioga Pharmaceuticals, and Vanda Pharmaceuticals. TB is, or has been, a lecturer or a consultant, or both, for Pfizer, AbbVie, Allmiral, AnaptysBio, Arena, Asana Biosciences, Astellas, BioVerSys, Boehringer Ingelheim, Celgene, Daichi-Sankyo, Davos Biosciences, Dermavant/Roivant, DermTreat, DS Pharma, Evaxion, FLX Bio, Galapagos/MorphoSys, Galderma, Glenmark, GlaxoSmithKline, Incyt, Kymab, LEO Pharma, Eli Lilly, L'Or{\'e}al/LaRochePossay, Menlo Therapeutics, Novartis, Pierre Fabre, Sanofi-Regeneron, UCB, and Vectans. JPT is an adviser, investigator, or speaker for Pfizer, AbbVie, Eli Lilly, LEO Pharma, Regeneron, and Sanofi-Genzyme. HV is an employee and shareholder of Pfizer. RR is an employee and shareholder of Pfizer. This Correspondence was funded by Pfizer, in accordance with Good Publication Practice guidelines. We thank Juan Sanchez-Cortes for editorial and medical writing support.",
year = "2021",
month = jan,
day = "16",
doi = "10.1016/S0140-6736(21)00037-4",
language = "English (US)",
volume = "397",
pages = "196",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10270",
}